Plain-English translation of NCT06088121 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a treatment system called ATNC MDD-V1, which combines two approaches: transcranial magnetic stimulation (a non-invasive way to stimulate the brain using magnetic pulses) and cognitive training (memory and thinking exercises). The study wants to see if this combination can help people who have been diagnosed with mild Alzheimer's disease improve their cognitive function and slow memory loss.
Current medications for Alzheimer's disease have limited effectiveness, and researchers are looking for new ways to help people in the early stages of the disease maintain their memory and thinking abilities. This trial is testing whether combining brain stimulation with cognitive training might offer additional benefit beyond medication alone.
You likely qualify if…
You likely don't qualify if…
If you qualify and are enrolled, you will be randomly assigned to receive either the real ATNC MDD-V1 treatment or a placebo version. Either way, you'll visit the clinic 5 days a week for 6 consecutive weeks, with sessions lasting about an hour each day. The real treatment combines magnetic brain stimulation with cognitive training exercises, while the placebo group receives sham (pretend) brain stimulation with real cognitive training. You'll then return for follow-up visits over the next several months to see how you're doing.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
South Korea